Table 5 Number, sales volume (in million SUs) and proportion (%) of the systemic antibiotic FDC formulations banned as a result of the second initiative
Formulations | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|---|---|---|---|
Banned in 2016 | No. | 68 | 68 | 59 | 60 | 57 | 52 | 37 | |
11.4% | 11.8% | 11.1% | 11.4% | 11.2% | 10.7% | 8.8% | |||
Vol | 345.2 | 365.1 | 382.3 | 271.9 | 229.6 | 195.8 | 25.6 | ||
6.5% | 6.6% | 6.5% | 4.9% | 4.4% | 3.9% | 0.5% | |||
Banned in 2017 | No. | 2 | 2 | 3 | 3 | 3 | 3 | 2 | |
0.3% | 0.4% | 0.6% | 0.6% | 0.6% | 0.7% | 0.5% | |||
Vol | 5.4 | 5.6 | 5.8 | 3.9 | 3.3 | 0.8 | < 0.1 | ||
0.1% | 0.1% | 0.1% | 0.1% | 0.1% | < 0.1% | < 0.1% | |||
Banned in 2018 | No. | 52 | 53 | 51 | 47 | 36 | 31 | ||
9.8% | 10.1% | 10.0% | 9.7% | 8.6% | 7.8% | ||||
Vol | 382.0 | 272.7 | 228.7 | 195.6 | 23.8 | 5.9 | |||
6.5% | 4.9% | 4.4% | 3.9% | 0.5% | 0.1% | ||||